The Oculis strategy is to build a innovative ophthalmology company unlike any other. Our plan is to:
Our novel formulation SNP technology provides an unprecedented technical advancement in ocular drug formulation, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
Our most advanced product candidate based on SNP technology is OCS-01, which recently completed two Phase 2 studies, one in DME and one in Pain and Inflammation following cataract surgery. The study in DME is the first proof-of-concept of a topical drug effect on a chronic retinal disease and is also a successful proof-of-concept for the SNP formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants. The study in post-cataract surgery is the first proof-of-concept of a once daily topical steroid for treating Inflammation and Pain following ocular surgery. OCS-01 is moving into phase III, following a positive End of Phase 2 meeting, in both indications.